DigitalTwin Organs System Receives FDA Approval: Drug Trials Can Now Be Validated in Virtual Human Organs First

On July 2, 2028, Siemens Healthineers announced that its DigitalTwin Organs system received FDA breakthrough device designation, permitting its use for data generation in preclinical drug trials. This means pharmaceutical companies can first simulate drug responses on patients' virtual organ models, significantly reducing the need for animal testing and early human trials.

DigitalTwin Organs works by constructing high-precision digital models of patients' organs based on their CT, MRI, and genomic data, including vascular networks, cell density, and metabolic states. Candidate drug molecules are then injected in the virtual environment to simulate drug distribution, metabolism, and effects within the organ.

Siemens Healthineers Digital Health President Bernd Montag said: "Traditional drug trials require years of animal testing and early human trials, costing billions. DigitalTwin Organs lets pharma companies complete equivalent-scale simulations in weeks, reducing preclinical costs by 80%."

First partners include Pfizer, Roche, and BeiGene. Pfizer R&D president Mikael Dolsten revealed the company has applied DigitalTwin Organs to preclinical screening of three oncology drug candidates, with one molecule showing a toxicity signal in the virtual liver model that animal testing had missed, preventing it from entering human trials and saving approximately $200 million in potential losses.

The technology's limitation lies in model accuracy depending on input data quality. If patient imaging resolution is insufficient or genomic data is incomplete, the digital model's predictive accuracy drops significantly.